Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Inotek Pharmaceuticals
33 Hayden Avenue 2nd Floor
Lexington, MA 02421
Phone: 781-676-2100
www.inotekcorp.com

Inotek is a leader in the development of innovative drugs to address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate trabodenoson has demonstrated clinically meaningful efficacy and tolerability in late-stage glaucoma clinical trials. The Company believes trabodenoson will be a first-in-class breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy eyes to maintain normal IOP.

Key Contact
Name
Paul G. Howes
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
09/27/13 $21,000,000 Horizon Technology Finance
Pitango Venture Capital
Rho Ventures
undisclosed
09/27/13 $7,000,000 Venture Debt Horizon Technology Finance
undisclosed